Caduet and Medrol in line as Hisun-Pfizer China JV kicks off
This article was originally published in Scrip
Pfizer and partner Zhejiang Hisun Pharmaceutical have formally inaugurated their Chinese joint venture through which both firms are looking to develop sales of off-patent drugs and branded generics mainly in China but also internationally.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?